CA2637075A1 - Process for the preparation of rapamycin derivatives - Google Patents

Process for the preparation of rapamycin derivatives Download PDF

Info

Publication number
CA2637075A1
CA2637075A1 CA002637075A CA2637075A CA2637075A1 CA 2637075 A1 CA2637075 A1 CA 2637075A1 CA 002637075 A CA002637075 A CA 002637075A CA 2637075 A CA2637075 A CA 2637075A CA 2637075 A1 CA2637075 A1 CA 2637075A1
Authority
CA
Canada
Prior art keywords
formula
compound
aryl
alkyl
arylthionocarbamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002637075A
Other languages
English (en)
French (fr)
Inventor
Murat Acemoglu
Sabine Pfeffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2637075A1 publication Critical patent/CA2637075A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA002637075A 2006-01-24 2007-01-22 Process for the preparation of rapamycin derivatives Abandoned CA2637075A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0601406.2 2006-01-24
GBGB0601406.2A GB0601406D0 (en) 2006-01-24 2006-01-24 Organic Compounds
PCT/EP2007/000514 WO2007085400A1 (en) 2006-01-24 2007-01-22 Process for the preparation of rapamycin derivatives

Publications (1)

Publication Number Publication Date
CA2637075A1 true CA2637075A1 (en) 2007-08-02

Family

ID=36060760

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002637075A Abandoned CA2637075A1 (en) 2006-01-24 2007-01-22 Process for the preparation of rapamycin derivatives

Country Status (11)

Country Link
US (1) US8138344B2 (enExample)
EP (1) EP1979359A1 (enExample)
JP (2) JP5416412B2 (enExample)
KR (1) KR101423343B1 (enExample)
CN (2) CN104211716A (enExample)
AU (1) AU2007209569B2 (enExample)
BR (1) BRPI0707330A2 (enExample)
CA (1) CA2637075A1 (enExample)
GB (1) GB0601406D0 (enExample)
RU (1) RU2448970C2 (enExample)
WO (1) WO2007085400A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
JP6378192B2 (ja) * 2012-11-13 2018-08-22 エルジー エレクトロニクス インコーポレイティド データ送信方法及び装置、並びにデータ送信方法及び装置
CN108864149B (zh) 2013-03-15 2022-04-05 生物传感器国际集团有限公司 雷帕霉素衍生物的纯化
EP3109250A1 (en) * 2015-06-23 2016-12-28 Synbias Pharma AG Method for the synthesis of rapamycin derivatives
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
LT3898637T (lt) 2018-12-18 2025-03-10 Novartis Ag Rapamicino dariniai
CA3127448C (en) 2019-01-22 2024-06-04 Aeovian Pharmaceuticals, Inc. Mtorc modulators and uses thereof
KR20260115158A (ko) 2019-03-26 2026-07-23 노파르티스 아게 이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도
CN115776907B (zh) 2020-03-27 2025-02-25 艾奥维安制药公司 Mtorc1调节剂及其用途
WO2026080482A1 (en) * 2024-10-07 2026-04-16 Tornado Therapeutics, Inc. Rapamycin derivatives and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
DE69624921T2 (de) * 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
IL150524A0 (en) * 2000-01-07 2003-02-12 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
US8138344B2 (en) 2012-03-20
RU2008134424A (ru) 2010-02-27
WO2007085400A1 (en) 2007-08-02
JP2009523836A (ja) 2009-06-25
BRPI0707330A2 (pt) 2011-05-03
JP5416412B2 (ja) 2014-02-12
RU2448970C2 (ru) 2012-04-27
GB0601406D0 (en) 2006-03-08
US20090012298A1 (en) 2009-01-08
CN104211716A (zh) 2014-12-17
KR101423343B1 (ko) 2014-07-24
CN101374847A (zh) 2009-02-25
EP1979359A1 (en) 2008-10-15
JP2013136631A (ja) 2013-07-11
KR20080090453A (ko) 2008-10-08
AU2007209569A1 (en) 2007-08-02
AU2007209569B2 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
AU2007209569B2 (en) Process for the preparation of rapamycin derivatives
MXPA06000951A (es) Sintesis regioselectiva de cci-779.
WO2010060197A1 (en) Method for synthesizing vitamin d analogs
KR100247214B1 (ko) 22 - 옥사콜레칼시페롤 유도체 및 그의 제조방법
CA2797999C (en) Process for the preparation of chiral hydrazides
JP2018080180A (ja) (2s,5r)−7−オキソ−6−スルホオキシ−2−[((3r)−ピペリジン−3−カルボニル)−ヒドラジノカルボニル]−1,6−ジアザ−ビシクロ[3.2.1]オクタン
GB2254612A (en) Conversion of ginkgolide c to ginkgolide b
JP2019089848A (ja) ラパマイシン誘導体の精製
US7217822B2 (en) Process for making cabergoline
AU2011254079A1 (en) Process for the preparation of rapamycin derivatives
CA2133961C (en) A process for the preparation of ribonucleotide reductase inhibitors
MX2008009469A (en) Process for the preparation of rapamycin derivatives
NZ516913A (en) Novel vitamin D analogues
WO2016090461A1 (en) Salts of prostaglandin analog intermediates
TT et al. Transformations of (γ-Piperidono) dibenzoaza-14-crown-4 Ethers
WO2011077174A1 (en) Process for preparing pharmaceutical compounds and intermediate compounds
RU2320649C9 (ru) СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 4,5,6,9-ТЕТРАГИДРОТИЕНО[3,2-d]АЗОЦИНОВ
JPS6213953B2 (enExample)
JPH03246264A (ja) 2―アミノペンタン酸化合物の新規な製造法
JPH0892203A (ja) β‐ケトチオアミド誘導体及びその製造方法
PL179576B1 (pl) Nowe pochodne witaminy D
JPH066549B2 (ja) 2−ヒドロキシメチル−2,5,12−トリヒドロキシ−1,2,3,4−テトラヒドロナフタセン−6,11−ジオンの製造方法
HK1218959B (en) Purification of rapamycin derivatives
JPWO1996001263A1 (ja) インドロカルバゾール誘導体の製造法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150820